severity

#ACTRIMS2022 ā€“ Blood NfL Levels May Help Quantify Relapse Severity

Measuring levels of the neurofilament light chain (NfL) protein in blood may be a way to “quantify” relapse severity and predict future disability in people with relapsing-remitting multiple sclerosis (RRMS). “Higher [blood] NfL levels during periods of active inflammation predicted more [brain] atrophy,” researchers wrote in an abstract titled…

Risk of Severe COVID-19 Not Raised by Immunosuppressive DMTs

Exposure to multiple sclerosis (MS) disease-modifying therapies (DMTs), and particularly immunosuppressive DMTs, does not increase the risk of developing a severe form of COVID-19, or of dying from the disease, when adjusting for known risk factors, an Austrian registry-based study found. These findings add to data showing no…

Burden of Multiple Sclerosis Relapses Is Underappreciated, Study Says

The burden of moderate-to-severe relapses in multiple sclerosis (MS) patients is underappreciated, according to a study sponsored by the pharmaceutical companyĀ Mallinckrodt. Researchers discussed the findings at the American Academy of Neurology’s 69th annual meeting in Boston, April 22-28. The title of the presentation was ā€œThe Economic Burden Of…

#CMSC16 – MS Mice Show Reduced Disease Severity After Treatment with Vegetable Compound

Research from Indiana University School of Medicine showed that D3T – a compound that triggersĀ copyingĀ of antioxidant genes and production of the antioxidant glutathione – delays disease development and lowers disease severity in experimental autoimmune encephalomyelitis (EAE) animal models. The models mimicked multiple sclerosis (MS) in humans, advancing further exploration…